The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer.

Abstract

In patients with pancreatic cancer, pretreatment NLR may be use as a prognostic factor in pancreatic cancer patients. Further studies with larger patient cohorts are warranted to to better clarify the prognostic value of pre-treatment peripheral blood counts in patients with cancer.